A detailed history of Martingale Asset Management L P transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Martingale Asset Management L P holds 50,437 shares of VERV stock, worth $271,351. This represents 0.01% of its overall portfolio holdings.

Number of Shares
50,437
Previous 50,437 -0.0%
Holding current value
$271,351
Previous $246,000 0.81%
% of portfolio
0.01%
Previous 0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$4.76 - $12.79 $102,006 - $274,089
21,430 Added 73.88%
50,437 $246,000
Q1 2024

May 14, 2024

BUY
$10.81 - $17.96 $8,702 - $14,457
805 Added 2.85%
29,007 $385,000
Q4 2023

Feb 12, 2024

BUY
$8.84 - $18.7 $68,819 - $145,579
7,785 Added 38.13%
28,202 $393,000
Q3 2023

Nov 14, 2023

BUY
$11.42 - $20.82 $233,162 - $425,081
20,417 New
20,417 $270,000
Q3 2022

Nov 14, 2022

BUY
$15.63 - $41.49 $254,346 - $675,166
16,273 New
16,273 $559,000

Others Institutions Holding VERV

About Verve Therapeutics, Inc.


  • Ticker VERV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,942,300
  • Market Cap $322M
  • Description
  • Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...
More about VERV
Track This Portfolio

Track Martingale Asset Management L P Portfolio

Follow Martingale Asset Management L P and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Martingale Asset Management L P, based on Form 13F filings with the SEC.

News

Stay updated on Martingale Asset Management L P with notifications on news.